Educational only — not medical advice. If you’re in crisis or thinking about suicide: call or text 988 (U.S.) or your local emergency number. Support resources. Under construction and review—see the updates log.

buspirone

Adjunctive therapy

Brand: BUSPAR

Published 2025-12-21 · Last reviewed 2025-12-28 · 4 references

Content sourced from FDA labeling (DailyMed) and peer-reviewed literature.

Print sheet Review evidence

At a glance

Class: Adjunctive therapy·Typical dose: Start 7.5 mg twice daily (or 5 mg three times daily); increase by ~5 mg/day every 2–3 days as tolerated.·Half-life: Single-dose range 2–3 h·LAI available: No

Class: Adjunctive therapy
Typical dose: Start 7.5 mg twice daily (or 5 mg three times daily); increase by ~5 mg/day every 2–3 days as tolerated.
Half-life: Single-dose range 2–3 h
LAI available: No

Quick answers

What is buspirone?: Buspirone (brand Buspar) is a non-benzodiazepine anxiolytic used for generalized anxiety disorder and chronic anxiety symptoms; it has no meaningful GABA activity and does not produce the same dependence and withdrawal risk profile as benzodiazepines.
What is BUSPAR?: BUSPAR is a brand name for buspirone.
What is BUSPAR (buspirone) used for?: Label indications include: Anxiety disorders or short-term relief of anxiety symptoms (label).
What drug class is BUSPAR (buspirone)?: Azapirone Anxiolytic.
What is the mechanism of action of BUSPAR (buspirone)?: Non-benzodiazepine anxiolytic; 5-HT1A partial agonist (azapirone).
What strengths does BUSPAR (buspirone) come in?: Tablets: 5 mg, 7.5 mg, 10 mg, 15 mg, 30 mg.

General information

Buspirone is a non-benzodiazepine anxiolytic (azapirone) used for generalized anxiety disorder and chronic anxiety symptoms. It does not act on GABA receptors and does not share the same dependence and withdrawal profile as benzodiazepines.

Clinical effect is delayed (often 2–4+ weeks), so buspirone is not a rescue medication for acute panic or agitation; it works best with scheduled dosing and measurement-based follow-up.

Because buspirone is not a controlled substance and is typically not intoxicating, it can be a good fit when misuse risk, cognitive impairment, or occupational driving concerns make benzodiazepines a poor option; it is also used as SSRI/SNRI augmentation for residual anxiety.

The buspirone compare view, the buspirone evidence feed, and the buspirone print page can support an anxiety plan that minimizes sedation and misuse risk.

U.S. approvals

Anxiety disorders / short-term relief of anxiety symptoms

Formulations & strengths

Tablets: 5 mg, 7.5 mg, 10 mg, 15 mg, 30 mg.

Generic availability

Widely available generically (Buspar is discontinued in many markets but commonly referenced).

Best suited for persistent anxiety (especially GAD) when sedation, fall risk, or misuse concerns make benzodiazepines undesirable; onset is delayed and requires expectation-setting. Benefit depends on adherence and consistent dosing rather than “as-needed” use; early follow-up is helpful, and stopping and switching or augmenting is common when there is no meaningful improvement after an adequate trial.

View labelExact

Mechanism of action

Refer to the Glossary entry on Neurotransmitters for background on receptor systems involved in serious mental illness.

Partial agonist at serotonin 5-HT1A receptors, modulating serotonergic tone in anxiety circuits.

Lacks clinically meaningful GABA-A activity, which is why it is not a reliable agent for acute anxiolysis or benzodiazepine withdrawal.

Minimal direct sedative-hypnotic activity is why buspirone is often preferred in older adults or polypharmacy, but it also means it will not “knock down” acute agitation the way benzodiazepines can.

5-HT1A partial agonism (primary).
Minimal direct sedative-hypnotic receptor activity compared with benzodiazepines or antihistamines.

Metabolism & pharmacokinetics

Metabolized primarily by CYP3A4 to multiple metabolites, including 1-PP.
Oral half-life of unchanged buspirone is ~2–3 hours (label).
Significant food effect; taking consistently with or without food reduces variability.
Short half-life is why dosing is typically divided (BID–TID) and why missed doses can lead to symptom recurrence.

Dosing & administration

Start 7.5 mg twice daily (or 5 mg three times daily); increase by ~5 mg/day every 2–3 days as tolerated.
Typical effective range 20–30 mg/day in divided doses; maximum 60 mg/day (label).
Abrupt changes in adherence can reduce benefit given the short half-life.
Buspirone is not used as a PRN rescue medication; scheduled dosing and reassessment after an adequate trial (often 4–6 weeks at a therapeutic dose) are typical before changing strategy.

Monitoring & labs

Follow-up within 2–4 weeks is commonly used to assess adherence, side effects, and whether anxiety symptoms are trending in the right direction.
Dizziness and activation are commonly tracked during titration; slower titration can help if patients feel “wired” or unsteady.
Interacting medications (CYP3A4 inhibitors/inducers) and food consistency (grapefruit) are worth reviewing when response changes.
If no meaningful benefit after an adequate trial, stopping and switching or augmenting is common rather than continuing indefinitely.

Sources: FDA/DailyMed label; guideline statements.

Adverse effects

FDA boxed warnings

Common side effects (≥10%)

Dizziness: Common early; slow position changes are often advised, and slower titration can help.
Nausea / GI upset: Often improves with food and gradual titration.
Headache: Often transient; symptom-targeted treatment and dose adjustments can help if persistent.
Restlessness: Activating symptoms may improve with slower titration or dose redistribution.

Other notable effects

Serotonin syndrome is rare but possible with serotonergic combinations; MAOIs are avoided.
Minimal sedation overall, though individual variability and polypharmacy can still produce impairment.
Activation (restlessness, jitteriness) can occur during titration; slow titration and dose redistribution can improve tolerability.

Interactions

MAOI coadministration is contraindicated (hypertensive reactions reported); allow adequate washout.
CYP3A4 inhibitors increase exposure; inducers may reduce efficacy.
Grapefruit juice is typically avoided (CYP3A4 interaction).
When used with other serotonergic agents (SSRIs/SNRIs, triptans, linezolid, tramadol), education about serotonin toxicity symptoms is appropriate, with prompt reassessment if agitation, tremor, or autonomic instability develop.

Other useful information

Expectation-setting for delayed onset and early follow-up (2–4 weeks) are commonly used to support adherence.
Buspirone does not treat benzodiazepine withdrawal; framing it as a direct “substitute” during tapers can set unrealistic expectations.
Often paired with psychotherapy and sleep/activation screening for a durable anxiety plan.
For adherence, dosing is often linked to daily routines (morning/evening), and food timing is kept consistent; BID regimens may reduce missed midday doses when feasible.
If there is no meaningful benefit after an adequate trial, reassess diagnosis (GAD vs panic vs substance-related anxiety), treat comorbid depression/PTSD, and consider switching or augmenting rather than escalating indefinitely.

References

Related hubs:SMI toolkit·Support resources